Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Prenetics Group ( (PRE) ) just unveiled an announcement.
Prenetics Global Limited, a Nasdaq-listed consumer health sciences company and parent of the fast-growing IM8 premium nutrition brand, is expanding its position in the global wellness market with science-backed supplements sold in over 30 countries. IM8, anchored by its all-in-one Daily Ultimate Essentials powder, targets the premium daily nutrition segment and has surpassed $100 million in annualized recurring revenue within 11 months of launch.
On March 3, 2026, Prenetics announced that its executive leadership team completed a second consecutive round of post-earnings open market share purchases, signaling confidence in the company’s fundamentals. During the February 23–27, 2026 trading window, executives bought 76,060 shares for about $1.3 million, bringing their cumulative personal investment across the November 2025 and February 2026 windows to roughly $2.75 million, with CEO Danny Yeung increasing his own stake to approximately $750,000 in the latest round and stating that the current share price does not yet reflect IM8’s performance and strengthening fundamentals.
The most recent analyst rating on (PRE) stock is a Hold with a $19.50 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
Spark’s Take on PRE Stock
According to Spark, TipRanks’ AI Analyst, PRE is a Neutral.
The score is primarily held back by weak financial performance (persistent losses and ongoing cash burn), despite improving revenue and gross margins and a currently strong balance sheet. The latest earnings call boosts the outlook with ambitious growth/margin guidance and strong liquidity, but near-term profitability remains negative and execution/concentration risks are material. Technicals are mixed with near-term weakness, and valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on PRE stock, click here.
More about Prenetics Group
Prenetics Global Limited (Nasdaq: PRE) is a consumer health sciences company focused on advancing human health and longevity through premium nutrition and wellness products. Its flagship brand IM8, co-founded with David Beckham and endorsed by tennis world No. 1 Aryna Sabalenka, offers science-backed daily nutrition such as the Daily Ultimate Essentials supplement, and has rapidly scaled past $100 million in annualized recurring revenue across more than 30 countries.
Average Trading Volume: 238,572
Technical Sentiment Signal: Buy
Current Market Cap: $266.6M
For a thorough assessment of PRE stock, go to TipRanks’ Stock Analysis page.